sprite-preloader
Anzeige
Mehr »
Sonntag, 15.07.2018 Börsentäglich über 12.000 News von 586 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Passende Knock-Outs zu Ihrer Suchanfrage (Anzeige)
Erweiterte
Suche
lynx
Ad hoc-Mitteilungen

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
15:35Vant commander Ramaswamy heads back to Nasdaq with a $150M pitch - are investors ready to forgive Axovant?
FrTaiho kicks off $130M Arcus deal with drug option; J&J allies with Merck KGaA to take diabetes drug to China
FrGeorge Golumbeski's first stop out of Celgene: Grail; Roivant taps Genentech vet Myrtle Potter for operations role
FrAfter long delay following patient death, FDA lifts trial hold on Advaxis/AstraZeneca combo
FrUPDATED: Senate Dems blast Novartis' ties to Trump attorney, claim pharma giant offered misleading explanations in damning report
FrBiogen vet George Scangos jumps on the board at upstart MS case manager Octave, backed by Section 32
FrAmgen, UCB are back pitching once-rejected osteoporosis drug romo to the FDA - but big hurdles lie ahead
DoInvestigative report calls for renewed scrutiny on Acadia drug; Imbruvica fails in frontline DLBCL PhIII
DoOn the heels of GW's epilepsy win, Wall Street darling Zogenix shares positive PhIII data on rival drug
DoHoping to shake Allergan/Shire's dry eye dominance, Oyster Point posts positive Phase IIb data for rival drug
DoFDA lays down the law on gene therapy, offering guidances on both diseases and procedures
DoRamaswamy's Dermavant bags GSK's PhIII-ready psoriasis drug in $330M deal - eyeing a major league contest
DoParker Institute scientists herald a cell therapy breakthrough in the lab, using next-gen CRISPR tech to engineer T cells
DoGenmab puts down $54M for immunotherapy collaboration - ready to spend millions more
DoVC money booms in Q2, with mega-deals hitting record levels
DoThiel-backed Compass adds $49M to A round, bringing total to $132M
MiSenator Wyden prods Trump/Pfizer for details, calling drug pricing stunt "long on theatrics, short on relief"
MiNovartis joins the Big Pharma exodus out of antibiotics, dumping research, cutting 140 and out-licensing programs
MiBristol-Myers Squibb's Opdivo/Yervoy combo scores colorectal cancer OK; Former Akebia, Merrimack staffers found guilty
MiPfizer reshuffles, splitting into three business units
Mi12 top China VCs you need to know who are making a transpacific splash (Part 2)
MiNovartis punts a late-stage PI3K drug with a worrying safety profile to one of China's upstart biotechs
MiOtsuka jumps into the US biotech M&A game, bagging Visterra in $430M buyout
MiTrump claims a big win over Big Pharma, forcing Pfizer to walk back drug price hikes
MiForbion raises $270M to tap the potential of European biotech plays